Experience in HIV patient care among physicians of the National Health Ministry;Experiencia en el manejo del paciente con VIH entre medicos de la Secretaria de Salud

Salud Publica de Mexico

Volumn 41, Issue 6, 1999, Pages 460-465

  Magis Rodríguez, Carlos ^a,b   Esquivel Pedraza, Lilly ^a   López Martínez, Carlos ^a  

^a Dir de Investigación   (Mexico)

^b NONE   (Mexico)

Author keywords

Acquired immunodeficiency syndrome therapy; HIV; Mexico; Physicians; Therapeutical approaches

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEXICO; OUTCOMES RESEARCH; PATIENT CARE; PHYSICIAN; VIRUS LOAD;

EID: 0342879914     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36341999000600005     Document Type: Article

References (21)

1. Mann JM, Tarantola DJM. HIV 1998: The global picture. Sci Am 1998;238:62-63.
2. The World Bank. Confronting AIDS: Public priorities in a global epidemic. NuevaYork: Oxford University Press, 1997.
3. Levy JA. HIV and the pathogenesis of AIDS. 2a. edición. Washington, D.C.: American Society for Microbiology, 1998.
4. Richman DD. How drug resistance arises. Sci Am 1998;238:68-69.
5. Adherence and the HIV community. BETA 1998:9-26.
6. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR. Dickinson GM et al. A controlled trial of early versus late treatment with zidovudine in symptomatic HIV infection. Results of the Veterans Affaires Cooperative Study. N Engl J Med 1993;326:437-443.
7. Bartlett JG, Moore RD. Improving HIV therapy. Sci Am 1998;238:64-68.
8. Phillips AN, Smith GD, Johnson M. Will we ever know when to treat HIV infection? BMJ 1996;313:608-610.
9. Mansfield S, Singh S. Who should fill the care gap in HIV disease? Lancet 1993;342:726-728.
10. Smith S, Robinson J, Hollyer J, Bhatt R, Ash S, Shaunak S. Combining specialist and primary health care teams for HIV positive patients. Retrospective and prospective studies. BMJ 1996;312:416-420.
11. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-1092.
12. Miles SA. Long-term therapeutic strategies in HIV. J Acquir Immune Defic Synd Hum Retrovirol 1997;16 Suppl 1:S36-S41.
13. Magis-Rodríguez C, Bravo-García E, Anaya-López L, Uribe-Zúñiga P. La situación del SIDA en México a finales de 1998. Enf Infec Microbiol Clin 1998;18:23-44.
14. Análisis de la situación del SIDA y las ETS del primer trimestre de 1998. SIDA/ETS 1998;4:48-62.
15. Saavedra-López JA, Magis-Rodríguez C. Costos y gastos en atención médica del SIDA en México. México, D.F: CONASIDA (Serie Ángulos del SIDA), 1998:51-57.
16. Actualización del cuadro básico y catálogo de medicamentos del Sector Salud. Diario Oficial de la Federación 1997 mayo 16; sección 1:28-31.
17. Fahey JL, Taylor JMG, Manna B, Nishanian P, Aziz N, Giorgi JV et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998;12:1581-1590.
18. Cozzi-Lepri A, Katzenstein TL, Ullum H, Phillips AN, Skinhoj P, Gerstoft J et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998;12:1639-1643.
19. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
20. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-629.
21. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians'experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-706.